These recommendations highlighted the importance of recording ethnicity, considering it as an ASCVD risk factor, and adjusting treatment based on ethnicity [i.e., Angiotensin-Converting Enzyme are not recommended as first-line therapy for uncomplicated hypertension in Black patients (40)]. This evidence concerns the gene ACE and Hypertension.